Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

Hearing Aids: A Review of What's New
Kim, Harold H., Barrs, David M.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | May 26, 2006 | Volume: 134 | Issue: 6 | Pages: 1043-1050

10.1016/j.otohns.2006.03.010 | PMID 16730553 Get It

OBJECTIVETo review the recent innovations in hearing aid technology.STUDY DESIGNReview of the literature.SETTINGPrivate tertiary referral otology/neurotology practice.RESULTSRecent innovations including digital signal processing (DSP), directional microphone technology, and open mold hearing aid fitting have resulted in improved satisfaction with current hearing aids.CONCLUSIONCurrent hearing aid technology with its innovations better meet needs of individuals who are hard of hearing.SIGNIFICANCEThe image commonly held of hearing aids by the general public is a negative one that can be improved with greater education.
Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension
Elliott, C. Gregory , Glissmeyer, Eric W. , Havlena, Gregory T., Carlquist, John F., McKinney, Jason T., Rich, Stuart , McGoon, Michael D., Scholand, Mary Beth , Kim, Miryoung, Jensen, Robert L., Schmidt, Jon W., Ward, Kenneth, Havlena, Gregory T.

Mayo Clinic

Circulation | May 22, 2006 | Volume: 113 | Issue: 21 | Pages: 2509-2515

10.1161/circulationaha.105.601930 | PMID 16717148 Get It

Background— Vasoreactivity tests are fundamental in evaluating pulmonary arterial hypertension (PAH). Mutations of the transforming growth factor-β type II receptor gene, BMPR2 , predispose to the development of pulmonary hypertension and may alter the response to vasodilators. Previous investigations have not examined the relationship of BMPR2 mutations to vasoreactivity. Methods and Results— We identified 133 consecutive unrelated patients with either idiopathic or familial PAH. Sixty-six patients were excluded because we lacked either DNA samples (n=18) or complete data from a vasoreactivity test (n=48). The remaining 67 patients were screened for BMPR2 DNA sequence variations, and specific variations were confirmed by gene sequencing. The vasoreactivity of patients with nonsynonymous BMPR2 variations was compared with that of patients without nonsynonymous BMPR2 variations. We found nonsynonymous BMPR2 variations in 27 of 67 patients with idiopathic (n=16 of 52) or familial (n=11 of 15) PAH. Vasoreactivity was identified in 3.7% of 27 patients with nonsynonymous BMPR2 variations and in 35% of 40 patients without nonsynonymous BMPR2 variations ( P =0.003). Five of the 27 nonsynonymous variations occur commonly in healthy individuals. None of the remaining 22 patients with BMPR2 variations demonstrated vasoreactivity, and the analysis remained unchanged when we assumed that nonsynonymous BMPR2 variations were present in all 15 patients with familial PAH. Conclusions— Patients with familial or idiopathic PAH and nonsynonymous BMPR2 variations are unlikely to demonstrate vasoreactivity. Further trials are required to determine whether long-term therapy can be directed by tests for BMPR2 variations.
Modulation of Proliferating Renal Epithelial Cell Affinity for Calcium Oxalate Monohydrate Crystals
Farell, Gerard, Huang, Eric , Kim, S.Y., Horstkorte, R., Lieske, John C.

Mayo Clinic

Journal of Urology | April 6, 2006 | Volume: 175 | Issue: 5 | Pages: 1748-1749

10.1016/s0022-5347(06)00198-4 Get It

Biomechanical Efficiency of Wrist Guards as a Shock Isolator
Hwang, Il-Kyu, Kim, Kyu-Jung, Kaufman, Kenton R. , Cooney, William P., An, Kai‐Nan , Kaufman, Kenton R

Mayo Clinic

Journal of Biomechanical Engineering | March 7, 2006 | Volume: 128 | Issue: 2 | Pages: 229-234

10.1115/1.2165695 | PMID 16524335 Get It

Despite the use of wrist guards during skate- and snowboard activities, fractures still occur at the wrist or at further proximal locations of the forearm. The main objectives of this study were to conduct a human subject testing under simulated falling conditions for measurement of the impact force on the hand, to model wrist guards as a shock isolator, to construct a linear mass-spring-damper model for quantification of the impact force attenuation (Q-ratio) and energy absorption (S-ratio), and to determine whether wrist guards play a role of an efficient shock isolator. While the falling direction (forward and backward) significantly influenced the impact responses, use of wrist guards provided minimal improvements in the Q- and S-ratios. It was suggested based on the results under the submaximal loading conditions that protective functions of the common wrist guard design could be enhanced with substantial increase in the damping ratio so as to maximize the energy absorption. This would bring forth minor deterioration in the impact force attenuation but significant increase in the energy absorption by 19%, which would help better protection against fall-related injuries of the upper extremity.
AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER DYSFUNCTION
Kim, Isaac Yi , Elliott, Daniel S. , Husmann, Douglas A. , Boone, Timothy B.

Mayo Clinic

Journal of Urology | January 18, 2006 | Volume: 165 | Issue: 3 | Pages: 903-904

10.1016/s0022-5347(05)66561-5 Get It

Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and Ratios
Oesterling, Joseph E., Jacobsen, Steven J. , Klee, George G., Petterson, Kim, Piironen, Timo, Abrahamsson, Per-Anders, Dowell, Barry L., Lövgren, Timo, Stenman, Ulf‐Håkan , Lilja, Hans

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 154 | Issue: 3 | Pages: 1090-1095

10.1016/s0022-5347(01)66984-2 | PMID 7543605 Get It

Clinical implication of centrosome amplification in plasma cell neoplasm
Ahmann, Greg, Henderson, Kim, Santana-Dávila, Rafael , Greipp, Philip R., Lacy, Martha Q. , Dispenzieri, Angela , Kumar, Shaji , Rajkumar, S. Vincent , Lust, John A., Kyle, Robert A. , Zeldenrust, Steven R., Hayman, Suzanne R. , Fonseca, Rafaël , Chng, Wee Joo , Henderson, Kimberly J., Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | December 23, 2005 | Volume: 107 | Issue: 9 | Pages: 3669-3675

10.1182/blood-2005-09-3810 | PMID 16373658 Get It

The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear. Centrosome amplification has been implicated as the cause of chromosomal instability in a variety of tumors and is a potential mechanism causing aneuploidy in MM. Using immunofluorescent (IF) staining, centrosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS). We also investigated the gene expression of centrosome proteins. Overall, gene expression data correlated well with IF-detected centrosome amplification, allowing us to derive a gene expression-based centrosome index (CI) as a surrogate for centrosome amplification. Clinically, MM patients with high CI (> 4) are associated with poor prognostic genetic and clinical subtypes (chromosome 13 deletion, t(4; 14), t(14;16), and PCLI > 1%, P < .05) and are shown here to have short survival (11.1 months versus 39.1 months, P < .001). On multivariate regression, a high CI is an independent prognostic factor. Given that centrosome amplification is already observed in MGUS and probably integral to early chromosomal instability and myeloma genesis, and patients with more extensive centrosome amplification have shorter survival, the mechanisms leading to centrosome amplification should be investigated because these may offer new avenues for therapeutic intervention.
Human TopBP1 Ensures Genome Integrity during Normal S Phase
Kim, Ja‐Eun , McAvoy, Sarah , Smith, David I., Smith, David I., Chen, Junjie

Mayo Clinic

Molecular and Cellular Biology | November 28, 2005 | Volume: 25 | Issue: 24 | Pages: 10907-10915

10.1128/mcb.25.24.10907-10915.2005 | PMID 16314514 Get It

Translational Crossroads for Biomarkers
Bast, Robert C. , Lilja, Hans , Rimm, David L. , Fritsche, Herbert A. , Veltri, Robert W., Klee, George G., Allen, Andrew R., Gutman, Steven, Rubin, Mark A. , Hruszkewycz, Andrew M., Urban, Nicole , Gray, Joe W. , Kim, Nam , Lilja, Hans , Bast, Robert C , Rimm, David , Rubin, Mark A

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 17 | Pages: 6103-6108

10.1158/1078-0432.ccr-04-2213 | PMID 16144908 Get It

Abstract A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute–supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development.
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Dy, Grace K. , Thomas, James P. , Wilding, George, Bruzek, Laura M., Mandrekar, Sumithra J. , Erlichman, Charles , Alberti, Dona, Binger, Kim, Pitot, Henry C., Hanson, Lorelei J., Marnocha, Rebecca, Tutsch, Kendra D., Adjei, Alex A. , Alberts, Steven R. , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 9 | Pages: 3410-3416

10.1158/1078-0432.ccr-04-2068 | PMID 15867242 Get It

Abstract Purpose: To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced malignancies. Patients and Methods: Twenty-eight patients (14 male and 14 female) received PS-341 twice weekly for 4 of 6 weeks (schedule I). Because toxicity necessitated dose omissions on this schedule, 16 additional patients (12 male and 4 female) received PS-341 twice weekly for 2 of every 3 weeks (schedule II). A total of 73 courses of treatment was given (median, 2; range, 1-4). Inhibition of 20S proteasome activity in peripheral blood mononuclear cells (PBMC) and accumulation of proteasome-targeted polypeptides in tumor tissue were evaluated as pharmacodynamic markers of PS-341 activity. Results: The most common toxicity was thrombocytopenia, which was dose limiting at 1.7 mg/m2 (schedule I) and 1.6 mg/m2 (schedule II), respectively. Sensory neuropathy was dose-limiting in a patient in schedule I. Grade ≥3 toxicities for schedule I were constipation, fatigue, myalgia, and sensory neuropathy. Grade ≥3 toxicities for schedule II were dehydration resulting from diarrhea, nausea and vomiting, fatigue, hypoglycemia, and hypotension. The maximum tolerated dose was 1.5 mg/m2 for both schedules. Reversible dose-dependent decreases in 20S proteasome activity in PBMCs were observed, with 36% inhibition at 0.5 mg/m2, 52% at 0.9 mg/m2, and 75% at 1.25 mg/m2. Accumulation of proteasome-targeted polypeptides was detected in tumor samples after treatment with PS-341. A patient with multiple myeloma had a partial response. Conclusion: PS-341 given 1.5 mg/m2 twice weekly for 2 of every 3 weeks is well tolerated and should be further studied.